d.ndiaye

TL2 · Bologna

Contributes reviews on supplier material. Based in Bologna.

Joined 9 April 2025 · last posted 2d

79 posts, newest first. Showing up to 150.

Reflectance and photometric devices: precision in practice — a second dataset Replied, post #82 · Analytics › Home & field testing · 26 Jul 2026 · 0 likes Picking up post #81: that is the part I would want checked first. A home refractometer is not measuring what people hope it is measuring in these preparations, and the…
Shoulders, tangent skims, and defensible integration Replied, post #20 · Analytics › HPLC & UHPLC · 24 Jul 2026 · 33 likes Adding thanks rather than a view. I do not have a view worth the space.
Tracking a shortage from primary sources rather than rumour Replied, post #114 · Access › Shortages · 21 Jul 2026 · 8 likes The published shortage register maintained by the national regulator is the authoritative source here, and it is updated far more often than any thread. Two people can…
Muscle cramps: the ordinary causes before the exotic ones — a second dataset Replied, post #62 · Practice › Side effects · 20 Jul 2026 · 17 likes The published rates come from populations that were titrated on a defined schedule with clinical supervision. Rates from a forum are not comparable and are biased by…
Impurity thresholds: where the common numbers come from Replied, post #2 · Analytics › Impurities & related substances · 10 Jul 2026 · 10 likes Oxidation at methionine and tryptophan: adds 16 per oxygen. Usually elutes earlier. Oxidation is common in storage, especially if the solution is exposed to light or if…
[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #67 · Access › International · 9 Jul 2026 · 14 likes Everything in post #65 holds. The case it does not cover is the one I have. The most useful thing anyone can add to a thin regional thread is what the official source…
Coming back to: A structured critique template this community uses Replied, post #52 · Evidence › Study critique · 7 Jul 2026 · 14 likes Taking post #49 at face value and following it one step further. Hold a trial to the standard something could actually have met. A criticism that no achievable design…
Coming back to: Why a preprint's supplementary material is often the best part Replied, post #95 · Evidence › Preprints · 3 Jul 2026 · 12 likes Where I part company with post #94, and it is a narrow parting. Author track record is a weak signal and it is a signal. A group that has published carefully for years…
Coming back to: Time to steady state after a dose increase Replied, post #91 · Pharmacology › Pharmacokinetics · 2 Jul 2026 · 30 likes Dose proportionality across the studied range means dose arithmetic behaves the way you would naively expect. It is worth checking whether it holds for a given compound…
Restarting after a long gap: what the labelling implies Replied, post #8 · Practice › Dosing & titration · 1 Jul 2026 · 31 likes Worth separating two things that post #6 runs together. Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes…
0.3 mL versus 0.5 mL versus 1 mL barrels: resolution matters Replied, post #82 · Devices › Syringes & needles · 23 Jun 2026 · 28 likes 0.3 ml versus 0.5 ml is one of those subjects where the general answer and the answer for a specific case diverge, and the thread will go in circles until someone says…
CJC-1295 with and without DAC: what the modification does Replied, post #90 · Compounds › Secretagogues & GH axis · 21 Jun 2026 · 8 likes Understood. Thank you for being specific about the limits of it.
A structured critique template this community uses — a second dataset Replied, post #12 · Evidence › Study critique · 17 Jun 2026 · 0 likes That is the distinction I keep failing to hold on to. Written down now.
Injecting into an area that has become firm: why not to Replied, post #63 · Practice › Administration · 13 Jun 2026 · 6 likes Needle length matters less than angle for subcutaneous delivery in most people. A short needle at ninety degrees and a longer one at forty-five put the material in…
Insurance and replacement policies, compared Replied, post #9 · marked as the solution · Sourcing › Logistics · 8 Jun 2026 · 9 likes Post #6 is right about the mechanism and I think understates the practical bit. Split shipments reduce single-point risk and increase the number of transits. Which…
Reading U-100 graduations, with a conversion table Replied, post #31 · Devices › Syringes & needles · 3 Jun 2026 · 12 likes Nothing here is medical advice, and anybody uncertain about technique can have it demonstrated by a nurse or a pharmacist in five minutes, which is a better use of the…
Comparing prices across jurisdictions without misleading yourself Replied, post #23 · Access › Pricing · 31 May 2026 · 6 likes Biosimilars and future generics: as patents expire, biosimilar and generic versions might become available and prices might fall. That has already happened for some…
A parcel stationary at a customs facility for nine days — does this still hold? Replied, post #23 · Sourcing › Logistics · 26 May 2026 · 0 likes A request rather than an answer: could whoever has the primary source for parcel stationary post it? I have seen the claim three times this month and each version had…
Journal club: LEADER as the historical anchor Replied, post #76 · Evidence › Journal club · 19 May 2026 · 0 likes Useful. I have added it to my own notes with the date on it.
Journal club: orforglipron phase 2 and the non-peptide question Replied, post #64 · Evidence › Journal club · 15 May 2026 · 3 likes The reason orforglipron phase 2 is hard to answer is that the obvious measurement and the relevant quantity are not the same thing, and substituting one for the other…
Prescription requirements and telehealth models — a second dataset Replied, post #29 · Sourcing › Regulatory · 14 May 2026 · 0 likes Before the thread moves on from Prescription requirements and telehealth models — what is the sample size behind the claim? I am not being difficult; I have seen the…
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile Replied, post #25 · Compounds › Semaglutide · 13 May 2026 · 24 likes The arithmetic in post #22 is right; the assumption feeding it is the part to check. Solutions of semaglutide can look faintly opalescent without anything being wrong.…
[2026 update] Storing lyophilised material long term: what governs the shelf life Replied, post #110 · Practice › Storage & stability · 5 May 2026 · 3 likes I have no financial interest in anything named in this thread and I want to say so before I comment on Storing lyophilised material long term, because it is the sort of…
Citation sweep results: how many references did not say what was claimed Replied, post #83 · Meta › Wiki maintenance · 24 Apr 2026 · 31 likes Post #82 answers the question as asked. The question underneath it is different. Careful with that. A short duplicated paragraph is sometimes better than a link,…
Spike-and-recover accuracy for a peptide assay Replied, post #58 · Analytics › Method validation · 9 Apr 2026 · 0 likes Adding the measurement that post #57 says would settle it. Limits of detection and quantitation: LOD is the lowest concentration that produces a signal above…
Follow-up: Request: a per-category review queue Replied, post #3 · Meta › Feature requests · 29 Mar 2026 · 26 likes This follows post #2 rather than contradicting it. Community support: if other people support your request, they can reply with "+1" or "I would use that too".…
Air bubbles in a subcutaneous injection: the honest risk assessment — does this still… Replied, post #27 · Practice › Administration · 25 Mar 2026 · 9 likes The thing about Air bubbles that took me longest to accept is that a plausible mechanism is not evidence of an effect. It is a reason to look, not a result.
What a good consultation looks like from the other side Replied, post #23 · Clinical › Prescriber conversations · 12 Mar 2026 · 30 likes This follows post #22 rather than contradicting it. Bringing a record of symptoms with dates and severities makes an assessment materially easier and is the single most…
The lowest dose that does anything: is that a real question? Replied, post #100 · Practice › Dosing & titration · 7 Mar 2026 · 27 likes If symptoms reset at each step, that is the expected pattern rather than a sign that the previous adaptation was imaginary. Every dose increase is a new exposure. Take…
Revisiting: Journal club: SURMOUNT-1, read without the press release Replied, post #21 · Evidence › Journal club · 27 Feb 2026 · 9 likes A request rather than an answer: could whoever has the primary source for SURMOUNT-1 post it? I have seen the claim three times this month and each version had lost a…
Mass error in ppm: the arithmetic and the caveat Replied, post #123 · Analytics › Mass spectrometry · 16 Feb 2026 · 4 likes Offering a way to settle mass error in ppm rather than another opinion about it. Two measurements, taken the same way, a fortnight apart. If the difference is within…
Pharmacy supply in the UK and the questions you will be asked Replied, post #33 · Regional › UK & Ireland · 7 Feb 2026 · 31 likes I would keep pharmacy supply and the decision it usually gets used for separate in this thread. They are related and they are not the same question, and merging them is…
Coming back to: Reading a supplier's product description as a marketing document Replied, post #5 · Compounds › Other compounds · 24 Jan 2026 · 8 likes Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its…
Storing lyophilised material long term: what governs the shelf life Replied, post #22 · Practice › Storage & stability · 11 Jan 2026 · 0 likes On post #18 — agreed on the reasoning, with one qualification. Storing lyophilised material long term: I would want to see the raw numbers rather than the summary…
Distinguishing expected GI effects from something that needs urgent attention Replied, post #30 · Practice › Side effects · 4 Jan 2026 · 33 likes The relationship between symptom burden and outcome is not what people assume. Feeling worse is not evidence of a larger effect and feeling nothing is not evidence of…
Reverse causation in a cohort study of weight and outcome Replied, post #13 · Evidence › Study critique · 2 Jan 2026 · 11 likes Worth separating two things that post #11 runs together. Distinguishing three things in the reverse causation discussion that keep getting used interchangeably: the…
What "verified" means on our vendor pages, stated narrowly Replied, post #13 · Sourcing › Vendor reports · 27 Dec 2025 · 0 likes Photograph the vial and the label before opening. It costs ten seconds and it is what turns a report into something checkable. Worth saying I have only my own numbers…
Robustness: the parameters worth deliberately varying Replied, post #46 · Analytics › Method validation · 6 Dec 2025 · 12 likes Post #43 answers the question as asked. The question underneath it is different. A definition problem is doing most of the work in this robustness discussion. Once the…
A widely repeated interaction claim that turns out to be unsupported Replied, post #9 · Practice › Interactions · 3 Dec 2025 · 10 likes Vitamins: most vitamins have no significant interaction. Fat-soluble vitamins (A, D, E, K) might be affected by the slowing of fat absorption during weight loss, but…
Why "any advice?" is the least effective ending for a post — the long version Replied, post #82 · Start Here › How to Ask · 7 Nov 2025 · 1 like Everything in post #80 holds. The case it does not cover is the one I have. Number your questions if there is more than one. It sounds fussy. It means the answer can be…
EMA product information as a primary source Replied, post #17 · Regional › European Union · 30 Oct 2025 · 18 likes One caution on EMA product information: everything above assumes the underlying documentation is what it claims to be. That assumption is doing real work and is rarely…
Coming back to: Why quantitation is the hard part, not detection Replied, post #83 · Analytics › Home & field testing · 23 Oct 2025 · 14 likes Distinguishing three things in the quantitation discussion that keep getting used interchangeably: the observation, the proposed mechanism, and the recommendation that…
Liver enzymes drifting down and what that usually means Replied, post #21 · Clinical › Bloodwork · 23 Oct 2025 · 29 likes Reference intervals: constructed to contain the central 95% of a reference population, which means one in twenty healthy people falls outside one by definition. Add…
What happens after your first post: likes, trust levels, and why none of it matters much… Replied, post #66 · Start Here › Welcome · 18 Oct 2025 · 28 likes Your introduction is well framed. You have given enough context that people can actually answer. That is rarer than it sounds and it matters more than it sounds. I…
Reverse causation in a cohort study of weight and outcome — a second dataset Replied, post #21 · Evidence › Study critique · 13 Sep 2025 · 1 like Worth separating two things that post #17 runs together. Small methodological point on Reverse causation: repeating a measurement is cheap and resolves most of what is…
Power cut for eleven hours: how I assessed it afterwards Replied, post #48 · Practice › Storage & stability · 7 Sep 2025 · 0 likes Reframing power cut for eleven hours slightly, because I think the disagreement is about the question rather than the answer. If the question is "does it happen", yes.…
[2026 update] Does dual agonism explain the effect size, or is it dose? Replied, post #11 · Compounds › Tirzepatide · 2 Sep 2025 · 0 likes I read post #7 twice before replying, because I had assumed the opposite. The 2.5 mg starting dose is a tolerance step and not a therapeutic one. Judging efficacy at…
Coming back to: Resolution and tailing factor: real acceptance criteria Replied, post #51 · Analytics › HPLC & UHPLC · 29 Aug 2025 · 29 likes Typical suitability criteria are a replicate area relative standard deviation below about two per cent, a tailing factor inside a defined window, a resolution minimum…
Reading a rodent study on a secretagogue without over-extrapolating Replied, post #39 · Compounds › Secretagogues & GH axis · 23 Aug 2025 · 16 likes What a well-designed human trial of a secretagogue would look like: randomised, placebo-controlled, adequate sample size, IGF-1 as primary outcome, muscle and strength…
Which panel is worth repeating and which is worth ignoring Replied, post #89 · Clinical › Bloodwork · 20 Aug 2025 · 6 likes Practical answer on panel, since the theoretical one is upthread: do the simplest check first, write down the result, and only then decide whether the complicated…
What a documentation review can and cannot tell you Replied, post #75 · Sourcing › Independent verification · 16 Aug 2025 · 0 likes Verified here means specific lots were independently measured on stated dates by named services and the results were consistent with the documentation. It is narrower…
Follow-up: Glucagon receptor agonism in a weight-loss compound Replied, post #3 · Pharmacology › Receptor biology · 29 Jul 2025 · 0 likes Receptor occupancy required for a clinical effect is not the same as full occupancy, and dose-response curves flattening at the top is what you would expect from that.
Revisiting: Reading a denial letter as a specification for your appeal Replied, post #41 · Access › Insurance & coverage · 11 Jul 2025 · 1 like Where an exception process exists separately from an appeal, they are different routes with different criteria and using the wrong one loses time. A single observation,…
Forced degradation studies: designing one that is informative — does this still hold? Replied, post #29 · Analytics › Method validation · 2 Jul 2025 · 0 likes This is the answer, and the reason it is the answer is the more useful part.
BPC-157: what the rodent literature actually shows, and what it does not — a second… Replied, post #64 · Compounds › Repair & healing peptides · 30 Jun 2025 · 13 likes Fine by me. I had wanted a stronger conclusion and there is not one available.
[2026 update] An appeal that failed, and what I would do differently Replied, post #108 · Access › Insurance & coverage · 14 Jun 2025 · 2 likes The denial letter is the specification for your appeal. It states a criterion, and the job is to demonstrate that the criterion is met in the letter's own language.
Coming back to: Getting a referral rather than a refusal Replied, post #65 · Clinical › Prescriber conversations · 13 Jun 2025 · 2 likes Post #62 is the version of this I will quote in future. One addition. The honest answer on Getting a referral is that it depends, and the useful part is the list of…
Follow-up: Tracking intake honestly when appetite is absent Replied, post #51 · Nutrition & Training › Protein & intake · 9 Jun 2025 · 12 likes Taking post #50 at face value and following it one step further. Tracking intake for a week rather than permanently is usually enough to find out whether there is a…
Splitting a vial for two laboratories: how to do it without ruining both Replied, post #56 · Sourcing › Independent verification · 7 Jun 2025 · 2 likes Worth stating the null on splitting a vial before we explain it: the observation may be nothing. That possibility deserves a sentence and usually does not get one.
Checking someone else's arithmetic: a worked example thread Replied, post #46 · Practice › Reconstitution · 10 May 2025 · 0 likes Picking up post #44: that is the part I would want checked first. A 10 mg vial reconstituted three different ways: 1 mL diluent gives 10 mg/mL, 2 mL gives 5 mg/mL, 4 mL…
[2026 update] US compounding rules and how they changed Replied, post #12 · Regional › North America · 8 May 2025 · 0 likes Nothing in this subcategory is medical or legal advice, and the clinicians posting here say so on their own account.
A well-designed study with a badly written abstract Replied, post #59 · Evidence › Study critique · 3 May 2025 · 0 likes I had written a reply contradicting post #57 and deleted it. Here is what survived. Reading this well-designed study thread as someone who came in with a fixed view:…
Second pass at: Retatrutide mass and identity: what a report should show Replied, post #33 · Compounds › Retatrutide · 1 May 2025 · 7 likes Picking up post #31: that is the part I would want checked first. Retatrutide is investigational. Anything obtained outside a trial is by definition research-use-only…
Second pass at: Triple agonism: additive, synergistic, or neither? Replied, post #26 · Compounds › Retatrutide · 17 Mar 2025 · 1 like Hepatic effects: glucagon receptor agonism promotes hepatic fat oxidation, which is mechanistically plausible for benefit in metabolic liver disease. Whether that…
Journal club: SURMOUNT-4 and continuation versus withdrawal — a second dataset Replied, post #3 · Evidence › Journal club · 14 Mar 2025 · 5 likes SURMOUNT-1 (N Engl J Med 2022): Tirzepatide obesity trial. The largest mean weight reduction for a pharmacological intervention at publication. Read the categorical…
Adducts: sodium, potassium, and the peak you did not expect Replied, post #14 · Analytics › Mass spectrometry · 19 Feb 2025 · 1 like On adducts the community has more anecdote than the confidence in this thread implies, and I include my own contribution in that.
When "no data" is the complete and final answer Replied, post #95 · Compounds › Other compounds · 17 Feb 2025 · 2 likes Where I part company with post #91, and it is a narrow parting. Dose conversions between related compounds in this subcategory are made far too casually. Structural…
Introducing myself and asking whether my planned first topic belongs anywhere Replied, post #3 · Start Here › Welcome · 5 Feb 2025 · 17 likes The compound pages are the fastest way to find out whether a question has a published answer at all. If the page says the trial is ongoing, that is the honest state of…
Escalating every six weeks instead of four: what I observed over eight months Replied, post #30 · Practice › Dosing & titration · 22 Jan 2025 · 1 like Fair, and the limits you put on it are the part I will remember.
Oral semaglutide bioavailability and its variability between people — a second dataset Replied, post #81 · Compounds › Oral incretins · 27 Dec 2024 · 15 likes I read post #77 twice before replying, because I had assumed the opposite. On Oral semaglutide bioavailability the community has more anecdote than the confidence in…
Follow-up: Tirzepatide's shorter half-life and its one practical consequence Replied, post #101 · Compounds › Tirzepatide · 21 Dec 2024 · 0 likes Comparisons between the tirzepatide and semaglutide programmes across trials rather than within one are weak. Different populations, different durations, different…
Reporting a good result: why nobody bothers and why they should — one year on Replied, post #6 · Sourcing › Vendor reports · 16 Nov 2024 · 25 likes Post #2 and I disagree about the size of the effect, not about the direction. Selective submission and selective reporting are the two easiest ways for a result to be…
Choosing which test to pay for, given a fixed budget — does this still hold? Replied, post #19 · Sourcing › Independent verification · 4 Nov 2024 · 0 likes Repeat testing: if you want to verify the same lot a second time, testing with a different service strengthens the conclusion. Testing with the same service verifies…
Meeting a protein target on a suppressed appetite — one year on Replied, post #10 · Nutrition & Training › Protein & intake · 12 Sep 2024 · 0 likes Building on post #7 rather than restating it. The reports here that describe what actually worked, in specifics, are far more useful than the ones stating a target. The…
Follow-up: Where the four-week escalation interval comes from, and what it is not Replied, post #41 · Practice › Dosing & titration · 8 Aug 2024 · 9 likes The four-week step is a trial convention, not a pharmacological constant. It is roughly four half-lives for a week-long half-life, which is the interval at which you…
Guidelines revision: what changed and why Replied, post #115 · Meta › Announcements · 28 Jul 2024 · 16 likes I read the earlier replies on guidelines revision twice before writing this, because I had assumed the opposite and wanted to be sure I was disagreeing with what was…
Follow-up: Conditions that change the calculus rather than forbidding it Replied, post #26 · Safety › Contraindications · 23 Jul 2024 · 0 likes I had written a reply contradicting post #24 and deleted it. Here is what survived. Where a condition appears as a warning rather than a contraindication, the decision…
Second pass at: Retatrutide dose escalation in the published trials Replied, post #59 · Compounds › Retatrutide · 20 Jul 2024 · 1 like Retatrutide is investigational. Material obtained outside a clinical trial is research-use-only by definition, is not approved for human use, and carries no assurance…
Oral contraceptives and delayed emptying: what the data shows Replied, post #13 · Practice › Interactions · 7 Jul 2024 · 0 likes Thyroid medications: semaglutide is associated with a slowing of gastric emptying, which might affect thyroid medication absorption if they are taken very close…